As prior analysis has demonstrated, the task of combining cytarabine:daunorubicin with various other anti-leukemic agents is that the dosing modifications necessary to avoid unacceptable toxicities may compromise treatment efficacy, stated Lawrence Mayer, PhD, president and head of analysis at Celator Pharmaceuticals. Prolongation of median survival relative to treatment with the individual agents, the principle efficacy outcome, was substantially greater for CPX-351 alone and for CPX-351 in conjunction with either agent. CPX-351 offers potent anti-leukemia activity only and in conjunction with other drugs in development for the treatment of leukemia, stated Scott Jackson, chief executive officer of Celator Pharmaceuticals.The prosthesis permits a nice decrease, and the postoperative x-rays look extremely anatomic.’ ‘The addition of the fracture prosthesis to the TITAN Modular Total Shoulder Program is certainly another great progression for Ascension,’ commented Guy Mayer, CEO and President of Ascension Orthopedics. ‘The recently released TITAN Fracture Prosthesis will end up being featured inside our upcoming anatomic abilities workshop, Redefining Modularity in Shoulder Arthroplasty, scheduled for April 9 in NEVADA, NV.’.

BrightFocus announces recipients of 2015 research program grants BrightFocus Foundation, which funds study worldwide on Alzheimer's disease, glaucoma, and macular degeneration, today announced that its 2015 study program grants have been awarded to 58 scientists in 20 says and 7 foreign countries.

.

Other Posts From Category "proctology":

Related Posts